Show simple item record

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

dc.contributor.authorYang, James Chih-Hsin
dc.contributor.authorHirsh, Vera
dc.contributor.authorSchuler, Martin
dc.contributor.authorYamamoto, Nobuyuki
dc.contributor.authorO'Byrne, Kenneth J
dc.contributor.authorMok, Tony S K
dc.contributor.authorZazulina, Victoria
dc.contributor.authorShahidi, Mehdi
dc.contributor.authorLungershausen, Juliane
dc.contributor.authorMassey, Dan
dc.contributor.authorPalmer, Michael
dc.contributor.authorSequist, Lecia V
dc.date.accessioned2014-07-18T10:34:25Z
dc.date.available2014-07-18T10:34:25Z
dc.date.issued2013-09-20
dc.identifier.citationYang JCH et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.2013, 31 (27):3342-50en_GB
dc.identifier.issn1527-7755
dc.identifier.pmid23816967
dc.identifier.doi10.1200/JCO.2012.46.1764
dc.identifier.urihttp://hdl.handle.net/10147/323400
dc.description.abstractPatient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subjectLUNG CANCERen_GB
dc.subjectQUALITY OF LIFEen_GB
dc.subject.meshAdenocarcinoma
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCisplatin
dc.subject.meshGlutamates
dc.subject.meshGuanine
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMutation
dc.subject.meshNeoplasm Staging
dc.subject.meshQuality of Life
dc.subject.meshQuinazolines
dc.subject.meshReceptor, Epidermal Growth Factor
dc.subject.meshTreatment Outcome
dc.titleSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.en_GB
dc.typeArticleen
dc.contributor.departmentJames Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Martin Schuler, West German Cancer Center, University Duisburg-Essen, Essen; Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; Kenneth J. O'Byrne, St James' Hospital, Dublin, Ireland; Tony S.K. Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong; Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell; Michael Palmer, Keele University, Keele, United Kingdom; and Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA.en_GB
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractPatient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.


This item appears in the following Collection(s)

Show simple item record